CN115969988A - 一种治疗新生血管性视网膜疾病的dna四面体药物复合物及其制备方法和用途 - Google Patents
一种治疗新生血管性视网膜疾病的dna四面体药物复合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN115969988A CN115969988A CN202211066316.1A CN202211066316A CN115969988A CN 115969988 A CN115969988 A CN 115969988A CN 202211066316 A CN202211066316 A CN 202211066316A CN 115969988 A CN115969988 A CN 115969988A
- Authority
- CN
- China
- Prior art keywords
- dna
- sirna
- group
- bevasiranib
- stranded dnas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 208000017442 Retinal disease Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 title description 9
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 108020004414 DNA Proteins 0.000 claims description 78
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 35
- 108020004459 Small interfering RNA Proteins 0.000 claims description 28
- 102000053602 DNA Human genes 0.000 claims description 20
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 20
- 206010029113 Neovascularisation Diseases 0.000 claims description 15
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 12
- 208000002780 macular degeneration Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 108091081021 Sense strand Proteins 0.000 claims description 9
- 230000030279 gene silencing Effects 0.000 claims description 9
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 7
- 201000011190 diabetic macular edema Diseases 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 230000006807 siRNA silencing Effects 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 206010066901 Treatment failure Diseases 0.000 claims description 3
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 229950006615 bevasiranib Drugs 0.000 abstract description 54
- PRYZSLKPMFOUNL-MHIBGBBJSA-N bevasiranib Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C(NC(=O)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 PRYZSLKPMFOUNL-MHIBGBBJSA-N 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 230000002207 retinal effect Effects 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 44
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 29
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 14
- 210000001525 retina Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 10
- 235000013601 eggs Nutrition 0.000 description 10
- 210000001508 eye Anatomy 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000012096 transfection reagent Substances 0.000 description 9
- 238000001890 transfection Methods 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 229960002833 aflibercept Drugs 0.000 description 6
- 108010081667 aflibercept Proteins 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 210000003837 chick embryo Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 210000003278 egg shell Anatomy 0.000 description 4
- 230000037440 gene silencing effect Effects 0.000 description 4
- 238000012226 gene silencing method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 238000013355 OIR mouse model Methods 0.000 description 3
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- 239000002525 vasculotropin inhibitor Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004155 blood-retinal barrier Anatomy 0.000 description 2
- 230000004378 blood-retinal barrier Effects 0.000 description 2
- 210000001775 bruch membrane Anatomy 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000001743 silencing effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000008069 Geographic Atrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000032436 Retinal depigmentation Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038862 Retinal exudates Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940027545 aflibercept injection Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 201000007917 background diabetic retinopathy Diseases 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- -1 hard exudation Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940005014 pegaptanib sodium Drugs 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供一种用于治疗新生血管性视网膜疾病的DNA四面体药物复合物,其由TDNs携载Bevasiranib形成的复合物,所述复合物展现出优异的新生血管生成的抑制作用,并显著改善了眼底渗漏情况,具有十分突出的视网膜修复作用。
Description
技术领域
本发明涉及针对新生血管性视网膜疾病的药物领域,具体而言,其涉及沉默VEGF的基因药物领域。
背景技术
新生血管性疾病是一类常见的致盲眼病,其包括年龄相关性黄斑变性(age-related macular degeneration,AMD)、糖尿病性黄斑水肿(diabetic macular edema,DME)等。这类疾病共同特点均在于新生血管的产生,使得疾病的治疗变得非常棘手,严重影响了患者的生存质量,给患者家庭及社会带来沉重的负担。在成人人群中,AMD的总患病率为8.69%,随着人口老龄化加剧,预计到2040年,全球将有AMD患者2.88亿人。DME是糖尿病的常见并发症之一,世界糖尿病联盟(IDF)的资料显示,中国2019年糖尿病患者人数高达1.6亿,其中DME的患病率约为4.6%。
目前的研究认为,VEGF作为最主要的新生血管生成刺激因子,在视网膜新生血管生成中发挥了重要的作用。在眼内,新生的血管在形态上与正常血管不同,其管腔不规则,管壁多为渗漏。这种高通透性或渗漏的血管的异常增生常导致视网膜上产生疤痕,并进一步可发生脱落从而影响到视力。
基于VEGF在新生血管性视网膜病变中的病理作用,VEGF抑制剂一度成为研发热点,其能够起到阻断VEGF与内皮细胞上VEGF受体之间的相互作用,从而阻止由VEGF介导的信息传导,抑制由VEGF高表达而引起的新生血管的生长的作用,以达到预防和阻止视网膜出血的目的。这类VEGF抑制剂包括Macugen(pegaptanib sodium),Lucentis,Aflibercept,Avastin(bevacizumab)和AdPEDF等。虽然上述VEGF抑制剂的出现,为眼底新生血管性疾病患者带来了希望,但当前的疗法不是普遍有效的,并且长期抑制VEGF可能导致组织萎缩和其他副作用,例如,每月注射抗VEGF药物与按需注射相比更易导致地图样萎缩,而注射次数增多与视网膜色素上皮萎缩的进展程度亦显著相关。因此,需要探索新的治疗方法和治疗药物来治疗异常血管生成,尽可能减轻患者和医生的负担,并且预防视网膜萎缩的发生,最大程度地改善患者的长期预后和生活质量。
RNA干扰是在许多真核生物中保守的转录后基因调控的方法。内源性或外源性dsRNA可被体内特定的核糖核酸酶(Dicer)切割成长度为21~23个碱基对的小双链片段。这些小的双链片段称为小干扰RNA(small interfering RNA,siRNA)。siRNA双链可与RNA诱导的基因沉默复合物(RNA-induced silencing complex,RISC)连接在一起,并在与RISC结合后,靶向切割特定mRNA为10~11个碱基的小片段,从而中断特定mRNA的翻译过程,抑制和沉默目的基因的表达。该过程中,siRNA可被循环利用,与多次周转酶十分相似,1个siRNA分子能够诱导约1000个mRNA分子的切割,可见针对具体靶点开发有效的siRNA药物能够极大地提高用药效率,对于需要通过长期抑制相关靶点进行疾病治疗的患者是非常具有前景的。
Bevasiranib是全球首个进入临床试验的siRNA药物,其是由Opko Health开发的针对VEGF靶点的21聚体siRNA,用于治疗AMD。然而,Bevasiranib的研发之路并不顺利,其虽然在I期和II期临床中展现出生物活性,但其III临床试验最终由于降低视力丧失的效果不佳而终止,至此,siRNA药物的首个治疗尝试因给药障碍而宣告失败。鉴于此,开发出siRNA递送平台,实现siRNA药物在体内的有效递送是迫在眉睫的现实需求。
DNA四面体(Tetrahedral DNA Nanostructures,TDNs)是一种由4条单链DNA通过变性和复性进而通过链间碱基互补配对形成的一种四面体结构,它易于合成,生物相容性高,专利CN109646450B中披露了TDNs在制备治疗角膜损伤的药物中的用途,专利CN112007044B中公开了TDNs-miR155复合物及其在制备预防或治疗湿性黄斑病变的药物中的用途,专利CN112843085B中公开了TDNs-miR22复合物及其在制备治疗视神经损伤的药物中用途。目前尚未见TDNs携载siRNA进行眼科疾病的治疗。
发明内容
针对上述技术问题,本发明的目的在于提供一种用于治疗新生血管性视网膜疾病的DNA四面体药物复合物,其由TDNs携载Bevasiranib形成的复合物,并进一步提供上述复合物在制备治疗新生血管性视网膜病变中的用途。
发明人惊喜地发现,虽然单独使用Bevasiranib的疗效有限,但在与TDNs形成复合物之后,无论是其入胞效率、蛋白沉默效果还是体内治疗活性均显著提升,展现出协同增效的作用,为弥补Bevasiranib的疗效缺憾提供了潜在的思路。
根据本发明的一方面,一种用于治疗新生血管性视网膜疾病的DNA四面体药物复合物,所述DNA四面体药物复合物包括:
(a)沉默VEGF基因的siRNA,所述siRNA包括如SEQ ID NO.5所示的核苷酸组成的有义链和如SEQ ID NO.6所示的核苷酸组成的反义链;和
(b)一DNA四面体,所述DNA四面体由四条单链DNA经碱基互补配对形成;所述四条单链DNA的核苷酸序列分别一对一地选自如SEQ ID NO.1~4的所示序列;
其中所述沉默VEGF基因的siRNA与DNA四面体的至少一条单链连接。
优选地,本发明所述的DNA四面体药物复合物,其中将所述沉默VEGF基因的siRNA的有义链以化学键与所述DNA四面体的至少一条单链连接。
更优选的是,本发明所述的DNA四面体药物复合物,其中在所述通过连接序列-TTTTT-将所述沉默VEGF基因的siRNA的有义链以化学键与所述DNA四面体的单链连接。
本发明所述的DNA四面体药物复合物,其中将形成所述DNA四面体的四条单链DNA以等摩尔比置于足以使其变性的温度下使其变性,然后将温度降低至使其退火进而通过链间碱基互补配对形成DNA四面体结构;再将所述四条单链DNA的至少一条连接所述沉默VEGF基因的siRNA。
根据本发明的另一方面,提供一种药物组合物,含有本发明所述的用于治疗新生血管性视网膜疾病的DNA四面体药物复合物。
根据本发明的再一方面,提供本发明所述的DNA四面体药物复合物或权本发明所述的药物组合物在制备治疗新生血管性视网膜疾病药物中的应用。
其中所述的新生血管性视网膜疾病包括年龄相关黄斑变性、糖尿病视网膜病变、糖尿病性黄斑水肿、视网膜静脉阻塞或由新生血管生长而引发的治疗失败。
DNA四面体
本发明所使用的DNA四面体,也即TDNs,是4条单链DNA经碱基互补配对形成;所述4条单链DNA的序列依次对应SEQ ID NO.1-4的所述序列,其可通过变性、退火过程组装形成目标产物TDNs。具体而言,将TDNs的4条单链DNA置于足以使其变性的温度下维持10min,再将温度降低至2-8℃维持20min以上。
优选地,所述DNA四面体是由所述4条DNA单链经90~98℃变性10~15min、2~8℃退火20~30min制备而成。
更优选地,所述DNA四面体是由所述4条DNA单链经95℃变性10min、4℃退火20min制备而成。
DNA四面体-Bevasiranib复合物
本发明的复合物是将DNA四面体和Bevasiranib(或称“沉默VEGF基因的siRNA”,在本发明中二者相互通用)按照1:(1-4)的摩尔比构成的复合物,其中Bevasiranib为siRNA双链体,其具有如SEQ ID NO:5所示的有义链和如SEQ ID NO:6所示的反义链,所述Bevasiranib通过化学键连接在DNA四面体结构中四条DNA单链中的一条、二条、三条和/或四条单链上,更进一步的,所述Bevasiranib和所连接DNA单链之间还含有连接序列,所述连接序列为核苷酸序列,优选为脱氧核糖核苷酸序列,更优选为-TTTTT-(即连续5个胸腺嘧啶脱氧核苷酸序列)。
具体地,上述复合物的制备方法,其通过将DNA四面体的4条单链DNA置于足以使其变性的温度下维持10min以上,再将温度降低到2~8℃维持20min以上;所述4条单链DNA的其中1条连接有Bevasiranib。
优选地,所述DNA四面体是由所述4条DNA单链经90~98℃变性10~15min、2~8℃退火20~30min制备而成,其中1条连接有Bevasiranib。
更优选地,所述DNA四面体是由所述4条DNA单链经95℃变性10min、4℃退火20min制备而成,其中1条连接有Bevasiranib。
制药用途与治疗方法
本发明提供上述复合物在制备新生血管性视网膜疾病的药物中的用途,包括但不限于年龄相关黄斑变性,糖尿病视网膜病变,糖尿病性黄斑水肿,视网膜静脉阻塞,由新生血管生长而引发的治疗失败。
本发明中,术语“新生血管性视网膜疾病”,指由于新生血管生长伴随出血、渗出、增生等病理性改变造成的致盲性玻璃体视网膜疾病。新生血管形成是很多重要眼部疾病的共同病理改变。
年龄相关性黄斑变性(age-related macular degeneration,AMD)是黄斑区结构的病理性衰老改变。可分为干性(非渗出性)或湿性(渗出性或新生血管性)2种类型。湿性AMD以脉络膜新生血管为突出特征,其是在疾病发展中后期,病理改变不断加重后,引起Bruch膜断裂,脉络膜毛细血管通过破裂的Bruch膜进入RPE下或视网膜神经上皮下,形成脉络膜新生血管(CNV),这也是对视力影响的最直接因素。由于新生血管管壁的结构异常,常发生血管的渗漏和出血,进而导致黄斑部出血、水肿等引发一系列的改变,加重视力的下降甚至是突然视力大幅下降,是AMD导致失明的主要原因。
糖尿病视网膜病变(DR)为一项比较严重的微血管并发症,其病理特征主要为新生血管形成以及视网膜血-视网膜屏障(BRB)被破坏等,糖尿病视网膜病变(DR)是糖尿病最常见的微血管并发症之一,是慢性进行性糖尿病导致的视网膜微血管渗漏和阻塞从而引起一系列的眼底病变,如微血管瘤、硬性渗出、棉絮斑、新生血管、玻璃体增殖、黄斑水肿甚至视网膜脱离。DR以是否有从视网膜发出的异常新生血管作为判断标准,可分为增殖性糖尿病视网膜病变和非增殖性糖尿病视网膜病变。
视网膜静脉阻塞是常见的眼底血管病,其病程长,视网膜长期缺血,缺血后诱发新生血管形成。
本发明中同时还介绍了相关疾病的治疗方法,上述复合物可以通过多种不同的给药途径施用于有需要的患者,其中包括但不限于静脉给药、玻璃体内注射、也可以通过其他眼部局部递送的方式基于一定剂型达到治疗眼疾的目的。
有益的效果
实验结果显示,本发明所提供的DNA四面体-Bevasiranib复合物通过DNA四面体携载siRNA,能够显著提高Bevasiranib的体外入胞效率,不仅在体外实现了优异的VEGF蛋白沉默效果,在体内的动物模型中,所述复合物展现出媲美甚至优于阳性对照阿柏西普的新生血管生成的抑制作用,并显著改善了眼底渗漏情况,具有十分突出的视网膜修复作用。
附图说明
图1为TDN以及TDN-Beva的聚丙烯酰胺凝胶电泳图;
其中泳道1为TDN样品、泳道2-6为TDN-Beva样品
图2为TDN以及TDN-Beva的毛细管电泳图;
图3为TDN以及TDN-Beva的透射电镜图;
图4为Bevasiranib、Bevasiranib-LipoRNAiMAX复合物、TDN、TDN-Bevasiranib复合物在不同细胞(HEK-293细胞、HUVEC细胞以及HREC细胞)中的入胞效率;
图5为各给药组施用后,不同细胞中VEGF基因沉默效果,其中包括空白组(control)、Bevasiranib组和Bevasiranib+Lipo组、不同浓度的TDN组(5nmol/L、10nmol/L、15nmol/L)、不同浓度的TDN-Beva组(5nmol/L、10nmol/L、15nmol/L);
图6为各给药组施用后,不同细胞(HEK-293细胞、HUVEC细胞以及HREC细胞)中VEGF蛋白表达抑制水平统计,其中包括空白组(control)、Bevasiranib组、Bevasiranib+Lipo组、TDN组、TDN-BEVA组;
图7为各给药组施用于鸡胚绒毛尿囊膜模型后,其新生血管抑制水平,包括空白组(control)、Aflibercept(阳性对照)组、Bevasiranib组、Bevasiranib+Invivofectamine(转染试剂)、TDN组、TDN-Bevasiranib组;
图8为各给药组施用于小鼠OIR模型后,各组小鼠视网膜中VEGF蛋白表达量的水平,包括空白组(control)、Bevasiranib组、Bevasiranib+Invivofectamine组、TDN组、TDN-Bevasiranib组;
图9为各给药组施用于小鼠OIR模型后,各组小鼠视网膜中新生血管面积统计结果,包括空白组(control)、Aflibercept(阳性对照)组、Bevasiranib+Invivofectamine组、TDN组、TDN-Bevasiranib组;
图10为OIR模型中各给药组小鼠视网膜新生血管生成情况及无血管区恢复情况;
图11为TDN-Bevasiranib连接示意图。
具体实施方式
以下通过对本发明较佳实施方式的描述,详细说明但不限制本发明。
材料来源:如非特别说明,本发明所使用的材料均为市售购买。
HEK-293购自上海景泽生物技术有限公司;
HREC细胞购自angiopromie公司;
HUVEC细胞购自澳赛尔斯生物;
LipoRNAiMAX(Lipo)购自赛默飞;
Invivofectamine试剂购买自赛默飞;
阿柏西普注射液(Aflibercept):购自拜耳医药保健有限公司,规格为40mg/ml/瓶;
C57/BL小鼠购买自斯贝福(北京)生物技术有限公司
实施例1合成方法
(1)TDNs的合成
将四条单链(S1,S2,S3,S4)按照等摩尔比(每条单链加入1μl浓度为100μM的储存液)加入到含有96μl的TM buffer(10mM Tris-HCl,50mM MgCl2,pH 8.0)的200μl EP管中,将反应液加热到95℃维持10min,然后快速降温到4℃维持20min合成了TDNs。
4条单链的序列(5′→3′)如下:
S1:ATTTATCACCCGCCATAGTAGACGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAA(SEQ ID NO.1);
S2:ACATGCGAGGGTCCAATACCGACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCG(SEQ ID NO.2);
S3:ACTACTATGGCGGGTGATAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCC(SEQ ID NO.3);
S4:ACGGTATTGGACCCTCGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCG(SEQ ID NO.4);
其中S1的5’端可选地连接一个Cy5荧光标记基团用于TDNs的示踪。
(2)TDNs-Bevasiranib复合物的合成
在实施例1的基础上,将S1序列替换为S1-Bevasiranib,其中S1通过连接序列-TTTTT-与Bevasiranib的有义链以化学键连接,将S1-Bevasiranib、S2、S3、S4按照等摩尔比(每条单链加入1μl浓度为100μM的储存液)加入到含有95μl的TM buffer(10mM Tris-HCl,50mMMgCl2,pH 8.0)的200μl EP管中,将反应液加热到95℃维持10min,然后快速降温到4℃维持20min合成了TDN-Bevasiranib(TDN-Beva),其连接方式如示意图(图11)所示。
Bevasiranib的有义链(SEQ ID NO.5):ACCUCACCAAGGCCAGCAC
Bevasiranib的反义链(SEQ ID NO.6):GUGCUGGCCUUGGUGAGGU-dTdT
实施例2表征
(1)鉴定方法
使用毛细管电泳、PAGE电泳检测DNA单链与合成得到的TDN-Beva;使用透射电镜检测TDNs与TDN-Beva的外形;使用动态光散射检测TDNs与TDN-Beva的zeta电位及粒径。
(2)结果
如图1-2所示,电泳结果指示TDNs-Beva的条带分子量符合TDNs与Beva的复合情况,表示Bevasiranib已成功连接至TDNs。
如图3所示,透射电镜图中可观测到TDNs以及TDNs-Beva的四面体结构颗粒。
根据动态光散色检测结果,TDNs颗粒和TDNs-Beva颗粒的粒径约为10nm-15nm,其中前者的zeta电位为-6.41mV,后者的zeta电位为-18.9mV。
实施例3细胞实验
(1)荧光标记细胞摄取实验
细胞:人胚胎肾细胞293(HEK-293)、人视网膜内皮细胞(HREC细胞)和人脐静脉内皮细胞(HUVEC)作为实验细胞
实验分组:空白组、Bevasiranib(Cy5标记)组、Bevasiranib(Cy5标记)+LipoRNAiMAX(转染试剂)组、TDN(Cy5标记)组、TDN-Bevasiranib(Cy5标记)组。
实验方法:
1)在转染实验的前一天,在每个孔的2ml生长培养基中加入3x10^5个细胞(确保转染时细胞密度在60-80%)。
2)使用DMEM培养基稀释各组样品至终体积250μl。
3)将待测样品添加到细胞中:每孔加样250μl,其最终样品浓度为15nmol/L。
4)37℃静置培养细胞24h,之后收样使用流式细胞仪检测入胞情况。
其中转染试剂的使用方法为:给细胞换液,加3%血清的培养基1.7mL。然后用147μl的无血清培养基加3μlBevasiranib混匀,141μl的无血清培养基加9μl转染试剂混匀,把两管液体混合,孵育5min,滴加至细胞中。
实验结果:
如图4所示,各细胞的入胞结果类似,空白组未检测到明显荧光信号(未呈现),Bevasiranib加转染试剂处理组的样本检测到明显的阳性荧光信号,入胞效率为90.0%左右,Bevasiranib无转染试剂处理组的样本则仅检测到微弱的荧光信号,入胞效率不超过2%,说明Bevasiranib自身的入胞能力不佳,在转染试剂的辅助下才能够有效入胞。TDN组与TDN-Beva处理组均检测到较强的阳性荧光信号,说明在不添加转染试剂的情况下TDN的携载能够实现Beva的高效入胞。
(2)VEGF基因沉默实验
细胞:人胚胎肾细胞293(HEK-293)、人视网膜内皮细胞(HREC细胞)和人脐静脉内皮细胞(HUVEC)作为实验细胞
实验分组:空白组、BEVA组、BEVA+Lipo组、5nmol/L TDN组、10nmol/L TDN组、15nmol/L TDN组、5nmol/L TDN-BEVA组、10nmol/L TDN-BEVA组和15nmol/L TDN-BEVA组
实验方法:
1)在转染实验的前一天,在每个孔的2ml生长培养基中加入3×10^5个细胞(确保转染时细胞密度在60-80%)。
2)使用DMEM培养基稀释各组样品至终体积250μl。
3)将待测样品添加到细胞中:每孔加样250μl,其中BEVA组、BEVA+Lipo组中siRNA的终浓度均为15nmol/L,其余给药组按照实验分组的浓度梯度为终浓度。
4)37℃静置培养细胞24h,之后收样进行qPCR实验检测基因沉默效果。
实验结果:
如图5所示,各细胞中基因沉默的作用趋势大致相同,其中不添加转染试剂处理的BEVA组与空白对照相比,并未展现出明显的差异性效果,而BEVA+Lipo组与空白组相比展现出一定的基因沉默作用。同时,TDN-BEVA组随浓度增大展现出明显的基因沉默作用,在相同浓度下与BEVA+Lipo组作用相当甚至更优。
(3)VEGF蛋白表达抑制实验
细胞:人胚胎肾细胞293(HEK-293)、人视网膜内皮细胞(HREC细胞)和人脐静脉内皮细胞(HUVEC)作为实验细胞
实验分组:空白组、Bevasiranib组、Bevasiranib+Lipo组、TDN组、TDN-Bevasiranib组
实验方法:
1)在转染实验的前一天,在每个孔的2ml生长培养基中加入3×10^5个细胞(确保转染时细胞密度在60-80%)。
2)使用0%FBS的培养基换液后,将各组样品添加到细胞中,六孔为一组,控制其终浓度为15nmol/L。
3)37℃静置培养细胞24h后收样,提取蛋白,检测蛋白浓度后进行WB实验,检测其VEGF的蛋白表达量。
实验结果:
如图6所示,蛋白定量的结果与前述基因沉默效果基本一致,其中TDN-Beva组展现出与Bevasiranib+Lipo组相当甚至更低的VEGF的表达量。
实施例4体内外模型实验
(1)鸡胚绒毛尿囊膜(CAM)新生血管抑制实验
实验分组:空白组、Aflibercept(阳性对照)组(1nmol/L)、Bevasiranib组(1nmol/L)、Bevasiranib(1nmol/L)+Invivofectamine(转染试剂)、TDN组(1nmol/L)、TDN-Bevasiranib组(1nmol/L)
实验方法:
用1:1000新洁尔灭液擦拭鸡蛋,将购买的SPF种鸡蛋表面清洁,拭干后用照蛋器检查种蛋是否完好,用铅笔标记实验名称,之后将鸡蛋放入孵化箱中孵化,条件设定为37.0±0.5℃,相对湿度60%,仪器设定每两个小时转蛋一次,继续孵育4-5天。
等鸡蛋孵育5-6d的时候,将实验用的鸡胚随机分为6组,每组5只。在照蛋器下用马克笔标记气室,画出开窗位置,用75%酒精消毒后,用注射器针头轻轻将蛋壳钻出一个小孔,之后用眼科镊在蛋壳上慢慢撕出一个直径约1cm窗口(用砂轮在,然后用眼科镊轻轻揭掉蛋膜,暴露鸡胚绒毛尿囊膜,注意不要损伤血管。滴加待测样品药液于绒毛尿囊膜上,之后用透明封口膜封闭窗口,孵育48h后,用酒精消毒接种部位及四周,撕去封闭处卵壳,滴入10%福尔马林液固定10min,待CAM上的血管凝固后,剥离假气室周围的蛋壳,使CAM充分暴露,用眼科剪取3cm×3cm的CAM,脱水后用石蜡包埋,平行于CAM方向,连续切片,厚度8μm,0.5%甲苯胺蓝染色。取标本于250倍视野下计数微血管的横截面,分别随机6个不重复的高倍视野,取其平均值(四舍五入)作为该标本的单位面积下的MVD(微血管密度),并计算器血管生成抑制率,计算方法如下:
血管生成抑制率=(空白组MVD值-实验组MVD值)/空白组MVD值*100%
实验结果:
如图7所示,阿柏西普(Aflibercept)阳性对照组展现出明显的新生血管抑制作用,而Bevasiranib+Invivofectamine组展现出优于Bevasiranib组的新生血管抑制活性,指示bevasiranib在转染试剂的作用下能够有效进入细胞并通过对VEGF的沉默表达作用产生一定的新生血管抑制效果。令人惊讶的是,单独的TDN展现出几乎与阳性对照组相当的新生血管抑制活性,其具体作用原理还有待进一步探究。同时,TDN-Beva组展现出极其优异的新生血管抑制活性,不仅显著优于阳性对照组,也优于Bevasiranib+Invivofectamine组和TDN组。
(2)氧诱导的血管增殖性视网膜病变(OIR)小鼠模型
造模过程:
将出生后第7天(P7)的C57/BL小鼠与母鼠放入含氧体积分数为75%±3%的饲养箱内连续饲养5天,饲养温度维持在(25±2)℃,每天照明12h,用自动氧气分析仪监控箱内氧气含量。出生后第12天(P12)放回正常空气中饲养,这时小鼠视网膜处于相对缺氧状态,出生后第17天(P17)视网膜内有大量新生血管形成。
1)小鼠视网膜VEGF蛋白表达量检测
实验分组及给药方式:
于P12出氧箱时进行玻璃体腔注射,各分组如下:
空白组:不进行玻璃体腔给药
Bevasiranib组:双眼玻璃体腔注射1μL的75μmol/L的Bevasiranib
Bevasiranib+Invivofectamine组:双眼玻璃体腔注射1μLsiRNA-Invivofectamine复合物,其中Bevasiranib的浓度为75μmol/L
TDN组:双眼玻璃体腔注射1μL75μmol/L TDNs
TDN-Bevasiranib组:双眼玻璃体腔注射1μL 75μmol/L TDN-Bevasiranib复合物
实验方法:
给药48h后,取各组小鼠3只,麻醉处死后取出双眼眼球共6只放入250μL细胞裂解液中,超声粉碎,低温超速离心30min,收集上清液,置于低温冰箱中保存。采用ELISA试剂盒检测视网膜蛋白提取液中VEGF表达。
实验结果:
如图8所示,Bevasiranib-Invivofectamine组相较于空白组展现出明显的VEGF表达抑制作用,而TDN-Bevasiranib组展现出优于Bevasiranib-Invivofectamine组的VEGF蛋白表达抑制效果,说明采用TDN载体携载Bevasiranib能够有效促进其入胞并沉默VEGF基因表达进而降低其蛋白表达量。
2)小鼠视网膜新生血管生成抑制实验
实验分组及给药方式:
于P12出氧箱时进行玻璃体腔注射,各分组如下:
空白组(negative CTRL):不进行玻璃体腔给药
Aflibercept(阳性对照)组:双眼玻璃体注射1μL 40mg/mL的阿柏西普
Bevasiranib+Invivofectamine组:双眼玻璃体腔注射1μLsiRNA-Invivofectamine复合物,其中Bevasiranib的浓度为75μmol/L
TDN组:双眼玻璃体腔注射1μL75μmol/L TDNs
TDN-Bevasiranib组:双眼玻璃体腔注射1μL 75μmol/L TDN-Bevasiranib复合物
实验方法:
于P17,取各组小鼠3只,麻醉处死后取出双眼眼球共6只,在10%的甲醛中室温固定半小时。显微镜下去除角膜、虹膜和晶体,小心完整地剥离视网膜,从视网膜锯齿缘到4个象限的赤道部做放射状切开,视网膜平铺在玻片上,水溶性封片剂封口,加盖玻片。用荧光显微镜检测平铺的视网膜,Image-Pro Plus(Media Cybernetics,美国)软件测量视网膜新生血管的面积。
实验结果:
如图9-10所示,空白组图片显示经过OIR造模的小鼠,其视网膜在P17产生了明显的病变,其视网膜在后极部形成无血管区(小圈内),以及新生血管区(小圈和大圈之间)。Aflibercept(阳性对照)组给药之后能够在一定程度上抑制新生血管的生成,并促进无血管区的血管正常化。类似的,TDN组展现出与Aflibercept(阳性对照)组接近的新生血管生成抑制效果。值得注意的是,TDN-bevasiranib组展现出明显优于阳性对照组的新生血管抑制作用,并能够明显促进无血管区的正常化,展现出对病变视网膜优异的修复作用。
本发明不限于以上实施方式,本领域技术人员可以根据说明书的描述对本发明做出各种改变或变形,只要不脱离本发明的精神,均属于本发明的范围。
序列:
SEQ ID NO.1
ATTTATCACCCGCCATAGTAGACGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAA;
SEQ ID NO.2
ACATGCGAGGGTCCAATACCGACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCG;
SEQ ID NO.3
ACTACTATGGCGGGTGATAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCC;
SEQ ID NO.4
ACGGTATTGGACCCTCGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCG;
SEQ ID NO.5
ACCUCACCAAGGCCAGCAC
SEQ ID NO.6
GUGCUGGCCUUGGUGAGGU-dTdT
Claims (10)
1.一种用于治疗新生血管性视网膜疾病的DNA四面体药物复合物,所述DNA四面体药物复合物包括:
(a)沉默VEGF基因的siRNA,所述siRNA包括如SEQ ID NO.5所示的核苷酸组成的有义链和如SEQ ID NO.6所示的核苷酸组成的反义链;和
(b)一DNA四面体,所述DNA四面体由四条单链DNA经碱基互补配对形成;所述四条单链DNA的核苷酸序列分别一对一地选自如SEQ ID NO.1~4的所示序列;
其中所述沉默VEGF基因的siRNA与DNA四面体的至少一条单链连接。
2.根据权利要求1所述的DNA四面体药物复合物,其中将所述沉默VEGF基因的siRNA的有义链通过化学键与所述DNA四面体的至少一条单链连接。
3.根据权利要求2所述的DNA四面体药物复合物,其中在所述沉默VEGF基因的siRNA的有义链与所述DNA四面体的至少一条单链之间还包含一接头。
4.根据权利要求3所述的DNA四面体药物复合物,其中所述接头为连接序列-TTTTT-。
5.根据权利要求1-4任一项所述的DNA四面体药物复合物,其中将形成所述DNA四面体的四条单链DNA以等摩尔比置于足以使其变性的温度下使其变性,然后将温度降低至使其退火进而通过链间碱基互补配对形成DNA四面体结构;将所述四条单链DNA的至少一条连接所述沉默VEGF基因的siRNA。
6.一种药物组合物,含有权利要求1所述的用于治疗新生血管性视网膜疾病的DNA四面体药物复合物。
7.权利要求1所述的DNA四面体药物复合物或权利要求6所述的药物组合物在制备治疗新生血管性视网膜疾病药物中的应用。
8.根据权利要求7所述的应用,其中所述的新生血管性视网膜疾病包括年龄相关黄斑变性、糖尿病视网膜病变、糖尿病性黄斑水肿、视网膜静脉阻塞或由新生血管生长而引发的治疗失败。
9.一种制备权利要求1所述的用于治疗新生血管性视网膜疾病的DNA四面体药物复合物的方法,包括将形成所述DNA四面体的四条单链DNA以等摩尔比置于足以使其变性的温度下使其变性,然后将温度降低至使其退火进而通过链间碱基互补配对形成DNA四面体结构;将所述四条单链DNA的至少一条连接所述沉默VEGF基因的siRNA。
10.根据权利要求9所述的方法,其中通过将所述DNA四面体的四条单链DNA置于足以使其变性的温度下维持10min以上,再将温度降低到2~8℃维持20min以上;在所述四条单链DNA的至少一条连接所述siRNA。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211066316.1A CN115969988A (zh) | 2022-09-01 | 2022-09-01 | 一种治疗新生血管性视网膜疾病的dna四面体药物复合物及其制备方法和用途 |
PCT/CN2022/121365 WO2024045250A1 (zh) | 2022-09-01 | 2022-09-26 | 一种治疗新生血管性视网膜疾病的dna四面体药物复合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211066316.1A CN115969988A (zh) | 2022-09-01 | 2022-09-01 | 一种治疗新生血管性视网膜疾病的dna四面体药物复合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115969988A true CN115969988A (zh) | 2023-04-18 |
Family
ID=85958686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211066316.1A Pending CN115969988A (zh) | 2022-09-01 | 2022-09-01 | 一种治疗新生血管性视网膜疾病的dna四面体药物复合物及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115969988A (zh) |
WO (1) | WO2024045250A1 (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080152654A1 (en) * | 2006-06-12 | 2008-06-26 | Exegenics, Inc., D/B/A Opko Health, Inc. | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
CN112007044B (zh) * | 2019-09-10 | 2021-11-12 | 四川大学 | 一种预防视网膜神经节细胞氧化应激和湿性黄斑病变的药物 |
CN112843085B (zh) * | 2021-03-18 | 2022-07-12 | 成都景润泽基因科技有限公司 | 一种治疗视神经疾病的复合物及其制备方法和用途 |
CN114404608B (zh) * | 2022-03-01 | 2023-02-03 | 四川大学 | 一种嵌入式搭载siRNA的四面体框架核酸及其用途 |
-
2022
- 2022-09-01 CN CN202211066316.1A patent/CN115969988A/zh active Pending
- 2022-09-26 WO PCT/CN2022/121365 patent/WO2024045250A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024045250A1 (zh) | 2024-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112007044B (zh) | 一种预防视网膜神经节细胞氧化应激和湿性黄斑病变的药物 | |
WO2024045251A1 (zh) | 一种治疗新生血管性视网膜疾病的小干扰rna及其dna四面体复合物 | |
Yang et al. | MiR-126 overexpression inhibits high glucose-induced migration and tube formation of rhesus macaque choroid-retinal endothelial cells by obstructing VEGFA and PIK3R2 | |
WO2020083007A1 (zh) | Sema4D/PlexinB1抑制剂在制备治疗及预防眼底血管疾病药物中的应用 | |
US10870852B2 (en) | Compositions and methods for treating diabetic retinopathy | |
CN112662674A (zh) | 靶向编辑VEGFA基因外显子区域的gRNA及其应用 | |
CN110251529A (zh) | miR-124-3p与其类似物在制备抗乳腺癌疾病药物中的应用 | |
CN109055561A (zh) | lncRNA-AP003774.1在诊断和/或治疗乳腺癌症中的应用 | |
Hnik et al. | Antisense oligonucleotide therapy in diabetic retinopathy | |
TW200916117A (en) | RNAi-related inhibition of TNF α signaling pathway for treatment of ocular angiogenesis | |
CN105727311A (zh) | Rnase4作为药物靶点在脑胶质瘤抑制药物中的应用 | |
CN115969988A (zh) | 一种治疗新生血管性视网膜疾病的dna四面体药物复合物及其制备方法和用途 | |
CN110066870B (zh) | hsa-miR-382-5p在制备诊断视网膜变性疾病的试剂盒中的应用 | |
CN110106248B (zh) | 环状RNA hsa_circ_0001543在制备视网膜变性疾病诊断试剂中的应用 | |
CN104995300A (zh) | Rna活性和血管通透性的调节 | |
CN104334195A (zh) | 包含抑制scf或者其受体的物质的用于治疗或预防血管渗透性相关疾病的组合物 | |
AU2013206951B2 (en) | Double-stranded RNA compounds to CASP2 and uses thereof | |
CN116459270B (zh) | 一种药物组合物及其在制备防治眼部新生血管性疾病药物中的应用 | |
CA2745111A1 (en) | Modulation of olfml-3 mediated angiogenesis | |
CN103361347B (zh) | 针对血管生成素2的微小rna | |
CN117448333B (zh) | 一种靶向DOCK6的siRNA与四面体框架核酸复合物及其应用 | |
US11566070B2 (en) | Agents that modulate TMEM230 as angiogenesis regulators and that detect TMEM230 as markers of metastasis | |
WO2023078099A1 (zh) | 一种用于治疗神经损伤疾病的基因药物 | |
Kumar et al. | Characterisation of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina | |
DK2257299T3 (en) | Modulation of SRPX2-mediated angiogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |